Background: Currently, the influence of microbiota on the occurrence, progression, and treatment of cancer is a topic of considerable research interest. Therefore, based on the theory of the gut-brain axis proved by previous studies, our objective was to uncover the causal relationship between glioblastoma and the gut microbiome using Mendelian randomization analysis. Methods: We conducted a bidirectional Mendelian randomization study using summary statistics of gut microbiota derived from the MiBioGen consortium, the largest database of gut microbiota. Summary statistics for glioblastoma were obtained from IEU OpenGWAS project, which included 91 cases and 218,701 controls. We assessed the presence of heterogeneity and horizontal pleiotropy in the analyzed data. We primarily employed the inverse variance weighting method to investigate the causal relationship between gut microbiota and glioblastoma after excluding cases of horizontal pleiotropy. Four other analysis methods were employed as supplementary. Excluding abnormal results based on leave-one-out sensitivity analysis. Finally, reverse Mendelian randomization analysis was performed. Results: Four genus-level taxa and one family-level taxa exhibited causal associations with glioblastoma. And these results of reverse Mendelian randomization analysis shown glioblastoma exhibited causal associations with three genus-level taxa and one family-level taxa. However, the Prevotella7(Forward, P=0.006, OR=0.34, 95%CI:0.158-0.732; Reverse, P=0.004, OR=0.972, 95%CI:0.953-0.991) shown the causal associations with glioblastoma in the bidirectional Mendelian randomization. Conclusions: In this bidirectional Mendelian randomization study, we identified five gut microbiota species with causal associations to glioblastoma. However, additional randomized controlled trials are required to clarify the impact of gut microbiota on glioblastoma and to reveal its precise mechanisms.
12 November 2024 in Ecotoxicology and Environmental Safety
An increasing number of environmental pollutants are associated with human diseases. We explored the mechanisms by which an aromatic small molecule -- Methyl-4-hydroxybenzoate (MEP) contribute to the development of glioblastoma (GBM). The causality of MEP and GBM were identified via the Mendelian Randomization (MR) analysis. We identified the key targets by integrating the targets of GBM, differential expressed genes (DEGs) from GEO and target genes of MEP. The network of hub genes was obtained from STRING and Cytoscape tools and GO, KEGG enrichment analysis were conducted by clusterProfiler R package. These hub targets were executed molecular docking via Autodock software. MEP had a causal association with GBM as risk factors (P < 0.05, OR > 1). 46 key targets were derived, in which CASP3, MMP2 and CDK4 were screened as the hub targets. MEP might play a role in the GBM by affecting the pathways of neuroactive ligand-receptor interaction, Molecular docking analysis showed a good binding ability of between MEP and CASP3, MMP2, CDK4, CASP8 and MCL1. A causal relationship between MEP and GBM exists. CASP3, MMP2, CDK4, CASP8 and MCL1 have been identified as the crucial targets correlating with GBM. This discovery may provide an important insight into how environmental pollutants contribute to the development of GBM.
Numerous studies have demonstrated a strong association between traumatic brain injury (TBI) and an increased risk of meningioma. However, this correlation remains controversial. This study utilized Mendelian randomization to explore this relationship from the perspective of genetic evidence. We employed 6 TBI genome-wide association study datasets from the integrative epidemiology unit genome-wide association study database. Summary statistics for meningioma were sourced from the FinnGen R10 database. We assessed heterogeneity and horizontal pleiotropy within the analyzed data. The primary method was inverse variance weighting (IVW) to investigate the causal relationship between TBI and meningioma, excluding cases with horizontal pleiotropy. Four supplementary analysis methods were also used, with abnormal results excluded based on leave-one-out sensitivity analysis. All 6 Mendelian randomization analyses indicated no causal relationship between TBI and meningiomas (focal brain injury IVW P value = 0.98; diffuse brain injury IVW P value = 0.41; TBI without concussion IVW P value = 0.45; intracranial trauma IVW P value = 0.34; traumatic subdural hemorrhage IVW P value = 0.80; traumatic subarachnoid hemorrhage IVW P value = 0.92). The Mendelian randomization study revealed that TBI does not increase the risk of meningioma based on genetic evidence.
Background: Glioblastoma (GBM) is a highly malignant central nervous system tumor with an exceptionally poor prognosis. The neuropeptide Galanin is implicated in GBM development, but its specific molecular mechanisms and therapeutic potential remain unclear. In this study, we integrate Mendelian randomization (MR) and network toxicology approaches to systematically characterize the pharmacological activity and mechanistic underpinnings of Galanin in GBM. Methods: A two-sample MR analysis was employed to investigate the causal relationship between Galanin and GBM risk. Galanin-related targets and differentially expressed genes were screened from public databases. Prognostic genes were identified through protein-protein interaction networks, single-cell sequencing, and the LASSO-COX model, and binding activity was validated by molecular docking. Finally, target genes were silenced using siRNA, and qRT-PCR, CCK-8, and colony formation assays were performed to validate the regulatory roles of CCNA2 and SERPINA1 in GBM cell proliferation. Results: The MR analysis confirmed a causal association between Galanin and GBM risk. Multidimensional bioinformatics identified four core genes: CCNA2, BRCA1, SERPINA1, and LGALS3. Molecular docking confirmed stable binding of Galanin to the proteins encoded by these genes. In vitro experiments demonstrated that silencing CCNA2 or SERPINA1 effectively inhibits GBM cell proliferation and colony formation. Conclusion: This study provides a comprehensive analysis of the regulatory mechanisms of Galanin in GBM from both genetic and computational toxicology perspectives. Our findings indicate that Galanin modulates CCNA2, BRCA1, SERPINA1, and LGALS3, likely through mediating the PI3K-Akt and focal adhesion signaling pathways, thereby hindering tumor progression. These results provide a foundational rationale for Galanin-targeted therapeutic strategies in GBM. Furthermore, the in vitro experiments corroborate that CCNA2 and SERPINA1 promote tumor cell proliferation, positioning them as promising therapeutic targets for GBM.